Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth. It was patented in the 1980s, and at the molecular level the active moiety is 1-hydroxy-2-(3-pyridinyl)ethylidene-1,1-bisphosphonic acid with molecular formula C7H11NO7P2 and molecular weight approximately 305 g/mol; the molecule binds strongly to hydroxyapatite in bone and inhibits osteoclast-mediated resorption principally by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway, producing reduced prenylation of small GTPases and decreased osteoclast activity and lifespan. Risedronate sodium is formulated for oral administration as tablets or effervescent tablets with low absolute bioavailability when taken with food, a short plasma elimination phase but prolonged skeletal retention, dosing instructions that require taking on an empty stomach with a full glass of water and remaining upright for at least 30 minutes to reduce esophageal exposure, and quality control attributes including assay, inorganic impurity limits, residual solvent limits, and stability indicating impurity profiles used in regulatory submissions.
Parent: Risedronate
Parent: Risedronate
Parent: Risedronate
Parent: Risedronate
Typical impurity control for risedronate active pharmaceutical ingredient and its sodium salt includes identification and quantitative control of related substances generated during synthesis and storage such as pyridyl-ring related analogs, hydrolysis products, N-oxides, dealkylated or reduced species, dimers and process-related residuals, plus control of residual solvents and inorganic counterions; manufacturers commonly set specification limits in the finished API dossier where individual known impurities are limited to the range of not more than 0.2 to 0.5 percent weight by weight, unspecified impurities are limited to not more than 0.1 to 0.2 percent w/w, and total impurities are typically limited to not more than 1.0 percent w/w, with tighter limits applied to genotoxic or toxicologically concerning degradants and qualification/identification thresholds established per ICH guidelines; exact impurity identities and acceptance criteria vary by manufacturer and regulatory filing and are verified by validated HPLC, MS and related analytical methods.
Risedronate is a bisphosphonate antiresorptive agent that inhibits osteoclast function by targeting farnesyl pyrophosphate synthase in the mevalonate pathway, leading to decreased bone resorption and increased bone mineral density.
You must remain upright for at least 30 minutes after oral dosing to reduce the risk of esophageal irritation, ulceration or reflux because contact of the tablet with the esophageal mucosa can cause local injury; the drug should be taken with a full glass of plain water on an empty stomach and no food, other medications or calcium-containing products should be taken for the recommended interval.
No, Fosamax is the trade name for alendronate, a different bisphosphonate molecule; both drugs share a similar antiresorptive mechanism but differ chemically, in recommended dosing regimens, and in some pharmacokinetic properties and specific clinical indications.
Common adverse effects include gastrointestinal complaints such as dyspepsia, abdominal pain, nausea and possible esophagitis; other effects can include musculoskeletal pain, hypocalcemia particularly in patients with vitamin D deficiency, and rare but serious events such as osteonecrosis of the jaw and atypical femoral fractures; patients should report severe or persistent symptoms to their prescriber and follow baseline calcium and vitamin D assessment and monitoring guidance.
